@ patients with minimally classic or occult subfoveal choroidal neovascularisation were randomly assigned to @ mg/mL TID , @ mg/mL TID , and @ mg/mL QD pazopanib eye drops for @ days in a multicentre , double-masked trial with an optional safety extension for up to @ additional months .